An open-label, parallel-group study to determine the single and multiple dose pharmacokinetics of vildagliptin and its metabolites in mild, moderate or severe renal impaired patients compared to age, sex and weight-matched healthy volunteers following daily doses of 50 mg vildagliptin for 14 days
Latest Information Update: 10 Dec 2007
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis
- 10 Dec 2007 New trial record.